Annovis Bio Files 8-K on Security Holder Vote
Ticker: ANVS · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Jun 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: ANVS
TL;DR
Annovis Bio (ANVS) filed an 8-K for a shareholder vote - details TBD.
AI Summary
Annovis Bio, Inc. filed an 8-K on June 13, 2024, to report on the submission of matters to a vote of its security holders. The filing does not contain specific details about the matters voted upon or the outcome of any vote.
Why It Matters
This filing indicates a corporate action involving shareholder voting, which could relate to significant company decisions or governance changes.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new financial or operational risks.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- June 13, 2024 (date) — Filing date and earliest event reported
- 101 Lindenwood Drive, Suite 225 (address) — Principal Executive Offices
- Malvern, PA 19355 (address) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Annovis Bio's security holders?
The filing states that matters were submitted to a vote, but does not specify what those matters were.
When did the earliest event reported in this 8-K occur?
The earliest event reported occurred on June 13, 2024.
What is Annovis Bio's principal executive office address?
The principal executive offices are located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
What is the Commission File Number for Annovis Bio?
The Commission File Number for Annovis Bio is 001-39202.
Was Annovis Bio previously known by another name?
Yes, Annovis Bio was formerly known as QR Pharma, Inc., with a name change date of December 2, 2009.
Filing Stats: 650 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-13 06:05:38
Filing Documents
- tm2417098d1_8k.htm (8-K) — 40KB
- 0001104659-24-071011.txt ( ) — 212KB
- anvs-20240613.xsd (EX-101.SCH) — 3KB
- anvs-20240613_lab.xml (EX-101.LAB) — 33KB
- anvs-20240613_pre.xml (EX-101.PRE) — 22KB
- tm2417098d1_8k_htm.xml (XML) — 4KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders . On June 12, 2024, Annovis Bio, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") virtually. At the Annual Meeting, three proposals were submitted to the Company's stockholders and all matters voted upon were approved with the required votes. The proposals are outlined below and further described in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission. At the Annual Meeting, a total of 7,278,396 shares of the Company's common stock, or 66.10% of the common stock outstanding as of April 18, 2024, the record date for the Annual Meeting, were represented virtually or by proxy. The following is a brief description of the final voting results for each of the three proposals submitted at the Annual Meeting on June 12, 2024: 1. Election of Directors All of the following five nominees were elected to the Company's Board of Directors, in accordance with the voting results listed below, to serve for a term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified. Nominee For Withheld Broker Non-Vote Michael Hoffman 3,856,586 122,626 3,299,184 Maria Maccecchini 3,888,261 90,951 3,299,184 Claudine Bruck 3,827,976 151,236 3,299,184 Reid McCarthy 3,845,664 133,548 3,299,184 Mark White 3,825,922 153,290 3,299,184 2. Amendment to the Company's 2019 Equity Incentive Plan Stockholders have approved an amendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan, to add 1,000,000 shares to the Plan's share reserve, in accordance with the voting results listed below: For Against Abstain 3,650,762 276,575 51,875 3. Ratification of the Company's Independent Auditors Stockholders ratified the appointment of Ernst & Young LLP as the independent auditors of the Company for the fiscal year ended December 31, 2024, in accordance with the voti
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO,INC. By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer Dated: June 13, 2024 3